Key facts
- This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Sep 2024, 21:20.
Eric M. Dube - 05 Sep 2024 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- TVTX
- Reported as of
- 05 Sep 2024
- Net transaction value
- -$243,360
- SEC form
- 4
- Accepted by SEC
- 09 Sep 2024, 21:20:12 UTC
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 23 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 09 Sep 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: -$243,360.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +32,500
- Change %
- +9.3%
- Price
- $0.000000
- Shares after
- 383,100
- Date
- 05 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
TVTX
transaction
Common Stock
Sale
- Transaction value
- $243,360
- Shares
- -21,125
- Change %
- -5.5%
- Price
- $11.52
- Shares after
- 361,975
- Date
- 09 Sep 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 32,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
Footnote F2
This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.